How herpes simplex virus-1 affects the release of tiny vesicles in the body
Cargo, biogenesis and functions of extracellular vesicles released during HSV-1 infection
This study is looking at how the herpes virus affects tiny particles that help cells communicate during an infection, which could give us clues about how the virus might be linked to diseases like Alzheimer's and help us find new ways to treat them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-10883705 on NIH RePORTER |
What this research studies
This research investigates how the herpes simplex virus-1 (HSV-1) influences the release of extracellular vesicles (EVs) during infection. These vesicles play a crucial role in cell communication and can affect the immune response and the progression of diseases like Alzheimer's. By examining two distinct populations of EVs produced during HSV-1 infection, the study aims to understand their functions and potential roles in both promoting and suppressing infections. The findings could provide insights into how HSV-1 contributes to neurodegenerative diseases and may lead to new therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a history of HSV-1 infection, particularly those experiencing cognitive decline or symptoms of Alzheimer's disease.
Not a fit: Patients without a history of HSV-1 infection or those not affected by neurodegenerative diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new ways to prevent or treat Alzheimer's disease and other neurodegenerative conditions linked to HSV-1.
How similar studies have performed: Previous research has shown that understanding the role of extracellular vesicles in viral infections can lead to significant advancements in treatment strategies, indicating a promising avenue for this study.
Where this research is happening
Kansas City, United States
- University of Kansas Medical Center — Kansas City, United States (Active)
Researchers
- Principal investigator: Kalamvoki, Maria — University of Kansas Medical Center
- Study coordinator: Kalamvoki, Maria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.